🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Screening of Predictive Biomarkers for Cardiorenal Syndrome

Recruitingn/aAges 18 Years - 75 YearsAllHaiyan Pan
NCT07139626 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to explore the predictive value of specific biomarkers for cardiorenal syndrome (CRS) in patients with chronic heart failure (CHF). Building on previous research using Luminex technology, which identified that serum levels of SLPI, serpin E1, CXCL10, and CXCL13 were significantly higher, while properdin levels were lower in patients with post-cardiac surgery acute kidney injury (AKI) compared to those without renal impairment, this study will further investigate these biomarkers in the context of CRS. Adults aged 18-75 with stable CHF (including HFrEF, HFmrEF, and HFpEF subtypes) will be conducted in two phases:1. Screening phase: Compare serum levels of the above biomarkers between 30 CHF patients without kidney dysfunction and 30 CHF patients with CRS to identify biomarkers with significant differences. 2. Validation phase: Follow 90 CHF patients with normal kidney fu

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 to 75 years. * Diagnosed with stable chronic heart failure (HF) according to the 2024 Chinese Heart Failure Diagnosis and Treatment Guideline. * HF subtypes include: HFrEF (LVEF ≤40%), HFmrEF (LVEF 41 - 49%), HFpEF (LVEF ≥50%). * Willing to provide blood samples for biomarker analysis. * Able to comply with follow - up visits and study procedures for 12 months. * Note: For the screening phase, 10 patients will be included for each subtype; for the validation phase, 30 patients will be included for each subtype. Exclusion Criteria: * History of long-term dialysis or kidney surgery. * Acute kidney injury (AKI) within the past 3 months. * Use of nephrotoxic drugs within the past 3 months. * Diagnosis of autoimmune diseases (e.g., lupus, rheumatoid arthritis). * Active malignancy or history of cancer treatment within the past 5 years. * Acute infectious diseases at the time of enrollment. * Severe liver dysfunction (e.g., cirrhosis, ALT/AST \>3× upper limit of normal). * Pregnancy or lactation. * Inability or unwillingness to provide informed consent. * Participation in another interventional clinical trial within the past 30 days.
💊

What it tests

  • This is an observational Study.
📍

Where

1 site
The Affiliated Hospital of Nantong University
Nantong, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy